The global market for Parkinsons Disease Drugs was valued at US$ 6212 million in the year 2024 and is projected to reach a revised size of US$ 9409 million by 2031, growing at a CAGR of 6.2% during the forecast period.

Parkinsons Disease Drugs Market

Most people with Parkinson"s disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Parkinsons Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinsons Disease Drugs.

The Parkinsons Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Parkinsons Disease Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Parkinsons Disease Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Parkinsons Disease Drugs Market Report

Report Metric	Details
Report Name	Parkinsons Disease Drugs Market
Accounted market size in year	US$ 6212 million
Forecasted market size in 2031	US$ 9409 million
CAGR	6.2%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Clinical Experiment
Segment by Application	Treament Prevention
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma, Sigma-Tau Group, Fudan-Zhangjiang, Teva Pharmaceutical, CSPC, Novartis, Kingond Pharm
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Parkinsons Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Parkinsons Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Parkinsons Disease Drugs Market growing?

Ans: The Parkinsons Disease Drugs Market witnessing a CAGR of 6.2% during the forecast period 2025-2031.

What is the Parkinsons Disease Drugs Market size in 2031?

Ans: The Parkinsons Disease Drugs Market size in 2031 will be US$ 9409 million.

Who are the main players in the Parkinsons Disease Drugs Market report?

Ans: The main players in the Parkinsons Disease Drugs Market are Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma, Sigma-Tau Group, Fudan-Zhangjiang, Teva Pharmaceutical, CSPC, Novartis, Kingond Pharm

What are the Application segmentation covered in the Parkinsons Disease Drugs Market report?

Ans: The Applications covered in the Parkinsons Disease Drugs Market report are Treament, Prevention

What are the Type segmentation covered in the Parkinsons Disease Drugs Market report?

Ans: The Types covered in the Parkinsons Disease Drugs Market report are Clinical, Experiment

1 Parkinsons Disease Drugs Market Overview

1.1 Product Definition

1.2 Parkinsons Disease Drugs by Type

1.2.1 Global Parkinsons Disease Drugs Market Value Comparison by Type (2024 VS 2031)

1.2.2 Clinical

1.2.3 Experiment

1.3 Parkinsons Disease Drugs by Application

1.3.1 Global Parkinsons Disease Drugs Market Value by Application (2024 VS 2031)

1.3.2 Treament

1.3.3 Prevention

1.4 Global Parkinsons Disease Drugs Market Size Estimates and Forecasts

1.4.1 Global Parkinsons Disease Drugs Revenue 2020-2031

1.4.2 Global Parkinsons Disease Drugs Sales 2020-2031

1.4.3 Global Parkinsons Disease Drugs Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Parkinsons Disease Drugs Market Competition by Manufacturers

2.1 Global Parkinsons Disease Drugs Sales Market Share by Manufacturers (2020-2025)

2.2 Global Parkinsons Disease Drugs Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Parkinsons Disease Drugs Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Parkinsons Disease Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Parkinsons Disease Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Parkinsons Disease Drugs, Product Type & Application

2.7 Global Key Manufacturers of Parkinsons Disease Drugs, Date of Enter into This Industry

2.8 Global Parkinsons Disease Drugs Market Competitive Situation and Trends

2.8.1 Global Parkinsons Disease Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Parkinsons Disease Drugs Players Market Share by Revenue

2.8.3 Global Parkinsons Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Parkinsons Disease Drugs Market Scenario by Region

3.1 Global Parkinsons Disease Drugs Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Parkinsons Disease Drugs Sales by Region: 2020-2031

3.2.1 Global Parkinsons Disease Drugs Sales by Region: 2020-2025

3.2.2 Global Parkinsons Disease Drugs Sales by Region: 2026-2031

3.3 Global Parkinsons Disease Drugs Revenue by Region: 2020-2031

3.3.1 Global Parkinsons Disease Drugs Revenue by Region: 2020-2025

3.3.2 Global Parkinsons Disease Drugs Revenue by Region: 2026-2031

3.4 North America Parkinsons Disease Drugs Market Facts & Figures by Country

3.4.1 North America Parkinsons Disease Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Parkinsons Disease Drugs Sales by Country (2020-2031)

3.4.3 North America Parkinsons Disease Drugs Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Parkinsons Disease Drugs Market Facts & Figures by Country

3.5.1 Europe Parkinsons Disease Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Parkinsons Disease Drugs Sales by Country (2020-2031)

3.5.3 Europe Parkinsons Disease Drugs Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Parkinsons Disease Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Parkinsons Disease Drugs Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Parkinsons Disease Drugs Sales by Region (2020-2031)

3.6.3 Asia Pacific Parkinsons Disease Drugs Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Parkinsons Disease Drugs Market Facts & Figures by Country

3.7.1 Latin America Parkinsons Disease Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Parkinsons Disease Drugs Sales by Country (2020-2031)

3.7.3 Latin America Parkinsons Disease Drugs Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Parkinsons Disease Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Parkinsons Disease Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Parkinsons Disease Drugs Sales by Country (2020-2031)

3.8.3 Middle East and Africa Parkinsons Disease Drugs Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Parkinsons Disease Drugs Sales by Type (2020-2031)

4.1.1 Global Parkinsons Disease Drugs Sales by Type (2020-2025)

4.1.2 Global Parkinsons Disease Drugs Sales by Type (2026-2031)

4.1.3 Global Parkinsons Disease Drugs Sales Market Share by Type (2020-2031)

4.2 Global Parkinsons Disease Drugs Revenue by Type (2020-2031)

4.2.1 Global Parkinsons Disease Drugs Revenue by Type (2020-2025)

4.2.2 Global Parkinsons Disease Drugs Revenue by Type (2026-2031)

4.2.3 Global Parkinsons Disease Drugs Revenue Market Share by Type (2020-2031)

4.3 Global Parkinsons Disease Drugs Price by Type (2020-2031)

5 Segment by Application

5.1 Global Parkinsons Disease Drugs Sales by Application (2020-2031)

5.1.1 Global Parkinsons Disease Drugs Sales by Application (2020-2025)

5.1.2 Global Parkinsons Disease Drugs Sales by Application (2026-2031)

5.1.3 Global Parkinsons Disease Drugs Sales Market Share by Application (2020-2031)

5.2 Global Parkinsons Disease Drugs Revenue by Application (2020-2031)

5.2.1 Global Parkinsons Disease Drugs Revenue by Application (2020-2025)

5.2.2 Global Parkinsons Disease Drugs Revenue by Application (2026-2031)

5.2.3 Global Parkinsons Disease Drugs Revenue Market Share by Application (2020-2031)

5.3 Global Parkinsons Disease Drugs Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Johnson & Johnson

6.1.1 Johnson & Johnson Company Information

6.1.2 Johnson & Johnson Description and Business Overview

6.1.3 Johnson & Johnson Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Johnson & Johnson Parkinsons Disease Drugs Product Portfolio

6.1.5 Johnson & Johnson Recent Developments/Updates

6.2 Gilead Sciences

6.2.1 Gilead Sciences Company Information

6.2.2 Gilead Sciences Description and Business Overview

6.2.3 Gilead Sciences Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Gilead Sciences Parkinsons Disease Drugs Product Portfolio

6.2.5 Gilead Sciences Recent Developments/Updates

6.3 Pacira

6.3.1 Pacira Company Information

6.3.2 Pacira Description and Business Overview

6.3.3 Pacira Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Pacira Parkinsons Disease Drugs Product Portfolio

6.3.5 Pacira Recent Developments/Updates

6.4 Sun Pharmaceutical

6.4.1 Sun Pharmaceutical Company Information

6.4.2 Sun Pharmaceutical Description and Business Overview

6.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Sun Pharmaceutical Parkinsons Disease Drugs Product Portfolio

6.4.5 Sun Pharmaceutical Recent Developments/Updates

6.5 Luye Pharma

6.5.1 Luye Pharma Company Information

6.5.2 Luye Pharma Description and Business Overview

6.5.3 Luye Pharma Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Luye Pharma Parkinsons Disease Drugs Product Portfolio

6.5.5 Luye Pharma Recent Developments/Updates

6.6 Sigma-Tau Group

6.6.1 Sigma-Tau Group Company Information

6.6.2 Sigma-Tau Group Description and Business Overview

6.6.3 Sigma-Tau Group Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Sigma-Tau Group Parkinsons Disease Drugs Product Portfolio

6.6.5 Sigma-Tau Group Recent Developments/Updates

6.7 Fudan-Zhangjiang

6.7.1 Fudan-Zhangjiang Company Information

6.7.2 Fudan-Zhangjiang Description and Business Overview

6.7.3 Fudan-Zhangjiang Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Fudan-Zhangjiang Parkinsons Disease Drugs Product Portfolio

6.7.5 Fudan-Zhangjiang Recent Developments/Updates

6.8 Teva Pharmaceutical

6.8.1 Teva Pharmaceutical Company Information

6.8.2 Teva Pharmaceutical Description and Business Overview

6.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Teva Pharmaceutical Parkinsons Disease Drugs Product Portfolio

6.8.5 Teva Pharmaceutical Recent Developments/Updates

6.9 CSPC

6.9.1 CSPC Company Information

6.9.2 CSPC Description and Business Overview

6.9.3 CSPC Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.9.4 CSPC Parkinsons Disease Drugs Product Portfolio

6.9.5 CSPC Recent Developments/Updates

6.10 Novartis

6.10.1 Novartis Company Information

6.10.2 Novartis Description and Business Overview

6.10.3 Novartis Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Novartis Parkinsons Disease Drugs Product Portfolio

6.10.5 Novartis Recent Developments/Updates

6.11 Kingond Pharm

6.11.1 Kingond Pharm Company Information

6.11.2 Kingond Pharm Description and Business Overview

6.11.3 Kingond Pharm Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Kingond Pharm Parkinsons Disease Drugs Product Portfolio

6.11.5 Kingond Pharm Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Parkinsons Disease Drugs Industry Chain Analysis

7.2 Parkinsons Disease Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Parkinsons Disease Drugs Production Mode & Process Analysis

7.4 Parkinsons Disease Drugs Sales and Marketing

7.4.1 Parkinsons Disease Drugs Sales Channels

7.4.2 Parkinsons Disease Drugs Distributors

7.5 Parkinsons Disease Drugs Customer Analysis

8 Parkinsons Disease Drugs Market Dynamics

8.1 Parkinsons Disease Drugs Industry Trends

8.2 Parkinsons Disease Drugs Market Drivers

8.3 Parkinsons Disease Drugs Market Challenges

8.4 Parkinsons Disease Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Parkinsons Disease Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Parkinsons Disease Drugs Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Parkinsons Disease Drugs Market Competitive Situation by Manufacturers in 2024

Table 4. Global Parkinsons Disease Drugs Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Parkinsons Disease Drugs Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Parkinsons Disease Drugs Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Parkinsons Disease Drugs Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Parkinsons Disease Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Parkinsons Disease Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Parkinsons Disease Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Parkinsons Disease Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Parkinsons Disease Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Parkinsons Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinsons Disease Drugs as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Parkinsons Disease Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Parkinsons Disease Drugs Sales by Region (2020-2025) & (K Units)

Table 18. Global Parkinsons Disease Drugs Sales Market Share by Region (2020-2025)

Table 19. Global Parkinsons Disease Drugs Sales by Region (2026-2031) & (K Units)

Table 20. Global Parkinsons Disease Drugs Sales Market Share by Region (2026-2031)

Table 21. Global Parkinsons Disease Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Parkinsons Disease Drugs Revenue Market Share by Region (2020-2025)

Table 23. Global Parkinsons Disease Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Parkinsons Disease Drugs Revenue Market Share by Region (2026-2031)

Table 25. North America Parkinsons Disease Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Parkinsons Disease Drugs Sales by Country (2020-2025) & (K Units)

Table 27. North America Parkinsons Disease Drugs Sales by Country (2026-2031) & (K Units)

Table 28. North America Parkinsons Disease Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Parkinsons Disease Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Parkinsons Disease Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Parkinsons Disease Drugs Sales by Country (2020-2025) & (K Units)

Table 32. Europe Parkinsons Disease Drugs Sales by Country (2026-2031) & (K Units)

Table 33. Europe Parkinsons Disease Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Parkinsons Disease Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Parkinsons Disease Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Parkinsons Disease Drugs Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Parkinsons Disease Drugs Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Parkinsons Disease Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Parkinsons Disease Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Parkinsons Disease Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Parkinsons Disease Drugs Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Parkinsons Disease Drugs Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Parkinsons Disease Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Parkinsons Disease Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Parkinsons Disease Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Parkinsons Disease Drugs Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Parkinsons Disease Drugs Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Parkinsons Disease Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Parkinsons Disease Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Parkinsons Disease Drugs Sales (K Units) by Type (2020-2025)

Table 51. Global Parkinsons Disease Drugs Sales (K Units) by Type (2026-2031)

Table 52. Global Parkinsons Disease Drugs Sales Market Share by Type (2020-2025)

Table 53. Global Parkinsons Disease Drugs Sales Market Share by Type (2026-2031)

Table 54. Global Parkinsons Disease Drugs Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Parkinsons Disease Drugs Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Parkinsons Disease Drugs Revenue Market Share by Type (2020-2025)

Table 57. Global Parkinsons Disease Drugs Revenue Market Share by Type (2026-2031)

Table 58. Global Parkinsons Disease Drugs Price (USD/Unit) by Type (2020-2025)

Table 59. Global Parkinsons Disease Drugs Price (USD/Unit) by Type (2026-2031)

Table 60. Global Parkinsons Disease Drugs Sales (K Units) by Application (2020-2025)

Table 61. Global Parkinsons Disease Drugs Sales (K Units) by Application (2026-2031)

Table 62. Global Parkinsons Disease Drugs Sales Market Share by Application (2020-2025)

Table 63. Global Parkinsons Disease Drugs Sales Market Share by Application (2026-2031)

Table 64. Global Parkinsons Disease Drugs Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Parkinsons Disease Drugs Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Parkinsons Disease Drugs Revenue Market Share by Application (2020-2025)

Table 67. Global Parkinsons Disease Drugs Revenue Market Share by Application (2026-2031)

Table 68. Global Parkinsons Disease Drugs Price (USD/Unit) by Application (2020-2025)

Table 69. Global Parkinsons Disease Drugs Price (USD/Unit) by Application (2026-2031)

Table 70. Johnson & Johnson Company Information

Table 71. Johnson & Johnson Description and Business Overview

Table 72. Johnson & Johnson Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Johnson & Johnson Parkinsons Disease Drugs Product

Table 74. Johnson & Johnson Recent Developments/Updates

Table 75. Gilead Sciences Company Information

Table 76. Gilead Sciences Description and Business Overview

Table 77. Gilead Sciences Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Gilead Sciences Parkinsons Disease Drugs Product

Table 79. Gilead Sciences Recent Developments/Updates

Table 80. Pacira Company Information

Table 81. Pacira Description and Business Overview

Table 82. Pacira Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Pacira Parkinsons Disease Drugs Product

Table 84. Pacira Recent Developments/Updates

Table 85. Sun Pharmaceutical Company Information

Table 86. Sun Pharmaceutical Description and Business Overview

Table 87. Sun Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Sun Pharmaceutical Parkinsons Disease Drugs Product

Table 89. Sun Pharmaceutical Recent Developments/Updates

Table 90. Luye Pharma Company Information

Table 91. Luye Pharma Description and Business Overview

Table 92. Luye Pharma Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Luye Pharma Parkinsons Disease Drugs Product

Table 94. Luye Pharma Recent Developments/Updates

Table 95. Sigma-Tau Group Company Information

Table 96. Sigma-Tau Group Description and Business Overview

Table 97. Sigma-Tau Group Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Sigma-Tau Group Parkinsons Disease Drugs Product

Table 99. Sigma-Tau Group Recent Developments/Updates

Table 100. Fudan-Zhangjiang Company Information

Table 101. Fudan-Zhangjiang Description and Business Overview

Table 102. Fudan-Zhangjiang Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Fudan-Zhangjiang Parkinsons Disease Drugs Product

Table 104. Fudan-Zhangjiang Recent Developments/Updates

Table 105. Teva Pharmaceutical Company Information

Table 106. Teva Pharmaceutical Description and Business Overview

Table 107. Teva Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Teva Pharmaceutical Parkinsons Disease Drugs Product

Table 109. Teva Pharmaceutical Recent Developments/Updates

Table 110. CSPC Company Information

Table 111. CSPC Description and Business Overview

Table 112. CSPC Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. CSPC Parkinsons Disease Drugs Product

Table 114. CSPC Recent Developments/Updates

Table 115. Novartis Company Information

Table 116. Novartis Description and Business Overview

Table 117. Novartis Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Novartis Parkinsons Disease Drugs Product

Table 119. Novartis Recent Developments/Updates

Table 120. Kingond Pharm Company Information

Table 121. Kingond Pharm Description and Business Overview

Table 122. Kingond Pharm Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 123. Kingond Pharm Parkinsons Disease Drugs Product

Table 124. Kingond Pharm Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. Parkinsons Disease Drugs Distributors List

Table 128. Parkinsons Disease Drugs Customers List

Table 129. Parkinsons Disease Drugs Market Trends

Table 130. Parkinsons Disease Drugs Market Drivers

Table 131. Parkinsons Disease Drugs Market Challenges

Table 132. Parkinsons Disease Drugs Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Product Picture of Parkinsons Disease Drugs

Figure 2. Global Parkinsons Disease Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Parkinsons Disease Drugs Market Share by Type: 2024 & 2031

Figure 4. Clinical Product Picture

Figure 5. Experiment Product Picture

Figure 6. Global Parkinsons Disease Drugs Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Parkinsons Disease Drugs Market Share by Application: 2024 & 2031

Figure 8. Treament

Figure 9. Prevention

Figure 10. Global Parkinsons Disease Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Parkinsons Disease Drugs Market Size (2020-2031) & (US$ Million)

Figure 12. Global Parkinsons Disease Drugs Sales (2020-2031) & (K Units)

Figure 13. Global Parkinsons Disease Drugs Average Price (USD/Unit) & (2020-2031)

Figure 14. Parkinsons Disease Drugs Report Years Considered

Figure 15. Parkinsons Disease Drugs Sales Share by Manufacturers in 2024

Figure 16. Global Parkinsons Disease Drugs Revenue Share by Manufacturers in 2024

Figure 17. Global 5 and 10 Largest Parkinsons Disease Drugs Players: Market Share by Revenue in Parkinsons Disease Drugs in 2024

Figure 18. Parkinsons Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 19. Global Parkinsons Disease Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 20. North America Parkinsons Disease Drugs Sales Market Share by Country (2020-2031)

Figure 21. North America Parkinsons Disease Drugs Revenue Market Share by Country (2020-2031)

Figure 22. U.S. Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 23. Canada Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Europe Parkinsons Disease Drugs Sales Market Share by Country (2020-2031)

Figure 25. Europe Parkinsons Disease Drugs Revenue Market Share by Country (2020-2031)

Figure 26. Germany Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. France Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. U.K. Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Italy Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Russia Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Asia Pacific Parkinsons Disease Drugs Sales Market Share by Region (2020-2031)

Figure 32. Asia Pacific Parkinsons Disease Drugs Revenue Market Share by Region (2020-2031)

Figure 33. China Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Japan Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. South Korea Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. India Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Australia Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Taiwan Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Indonesia Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Thailand Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Malaysia Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Philippines Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Parkinsons Disease Drugs Sales Market Share by Country (2020-2031)

Figure 44. Latin America Parkinsons Disease Drugs Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Parkinsons Disease Drugs Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Parkinsons Disease Drugs Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. U.A.E Parkinsons Disease Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Parkinsons Disease Drugs by Type (2020-2031)

Figure 54. Global Revenue Market Share of Parkinsons Disease Drugs by Type (2020-2031)

Figure 55. Global Parkinsons Disease Drugs Price (USD/Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of Parkinsons Disease Drugs by Application (2020-2031)

Figure 57. Global Revenue Market Share of Parkinsons Disease Drugs by Application (2020-2031)

Figure 58. Global Parkinsons Disease Drugs Price (USD/Unit) by Application (2020-2031)

Figure 59. Parkinsons Disease Drugs Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Autism Drug Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9T16706

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global ADHD Planner App Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34C16185

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Autism Digital Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2E16662

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-25A16539

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions